Adalimumab is a fully human monoclonal antibody that binds tumor necrosis factor (TNF)-␣. Its efficacy as maintenance therapy for patients with ulcerative colitis has not been studied in a controlled, double-blind trial. METHODS: Ulcerative colitis long-term remission and maintenance with adalimumab 2 (ULTRA 2) was a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of adalimumab in induction and maintenance of clinical remission in 494 patients with moderateto-severe ulcerative colitis who received concurrent treatment with oral corticosteroids or immunosuppressants. Patients were stratified based on prior exposure to TNF-␣ antagonists (either had or had not been previously treated with anti-TNF-␣) and randomly assigned to groups given adalimumab 160 mg at week 0, 80 mg at week 2, and then 40 mg every other week or placebo. Primary end points were remission at weeks 8 and 52. RESULTS: Overall rates of clinical remission at week 8 were 16.5% on adalimumab and 9.3% on placebo (P ϭ .019); corresponding values for week 52 were 17.3% and 8.5% (P ϭ .004). Among anti-TNF-␣ naïve patients, rates of remission at week 8 were 21.3% on adalimumab and 11% on placebo (P ϭ .017); corresponding values for week 52 were 22% and 12.4% (P ϭ .029). Among patients who had previously received anti-TNF agents, rates of remission at week 8 were 9.2% on adalimumab and 6.9% on placebo (P ϭ .559); corresponding values for week 52 were 10.2% and 3% (P ϭ .039). Serious adverse events occurred in 12% of patients given adalimumab or placebo. Serious infections developed in 1.6% of patients given adalimumab and 1.9% given placebo. In the group given adalimumab, 1 patient developed squamous cell carcinoma and 1 developed gastric cancer. CONCLUSIONS: Adalimumab was safe and more effective than placebo in inducing and maintaining clinical remission in patients with moderate-to-severe ulcerative colitis who did not have an adequate response to conventional therapy with steroids or immunosuppressants.
T he proinflammatory cytokine tumor necrosis factor-␣ (TNF-␣) plays an important role in the pathogenesis of ulcerative colitis (UC). 1 Intravenous administration of infliximab, a chimeric IgG1 monoclonal antibody to TNF-␣, is effective for induction and maintenance of remission in outpatients with moderate-to-severe UC who fail conventional therapy with steroids and/or immunosuppressive agents. 2 In a related condition, Crohn's disease, 2 subcutaneously administered anti-TNF-␣ agents are approved in the United States, and are preferred by some patients because they can be self-administered. [3] [4] [5] [6] [7] At present, no subcutaneously administered anti-TNF-␣ agents are approved for patients with UC.
Adalimumab is a fully human IgG1 monoclonal antibody directed against TNF-␣ that inhibits activity of this cytokine by blocking the interaction of TNF-␣ with its p55 and p75 cell surface receptors. Adalimumab is approved in the United States, Europe, and Japan for Crohn's disease, rheumatoid arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, and psoriasis. Several small open-label trials and case reports have suggested that adalimumab might be effective therapy for UC. 8 -11 Recently, an 8-week randomized controlled trial demonstrated the ability of adalimumab to induce clinical remission in patients with moderate-tosevere UC, and demonstrated that an induction regimen of subcutaneous adalimumab 160 mg at week 0, 80 mg at week 2, and 40 mg every other week (EOW) was more effective than placebo or adalimumab 80 mg at week 0, 40 mg at week 2, and then 40 mg EOW ulcerative colitis long-term remission and maintenance with adalimumab 1 (ULTRA 1). 12 Although this trial established the safety and efficacy of adalimumab for inducing clinical remission, higher than expected response rates were seen in placebo patients for several secondary end points, including clinical response and mucosal healing. To date, no controlled data regarding long-term (1 year) efficacy of adalimumab in patients with UC are available, and additional data regarding the induction efficacy of adalimumab for therapy in UC would be of interest. Accordingly, we designed the ulcerative colitis longterm remission and maintenance with adalimumab 2 (ULTRA 2) trial, a 52-week placebo-controlled induction and long-term treatment study in patients with moderate-to-severe UC.
Materials and Methods Patients
This phase 3, multicenter, randomized, double-blind, placebo-controlled trial was conducted at 103 centers in North America, Europe, Australia, New Zealand, and Israel between November 2006 and March 2010. The protocol was approved by the institutional review board for each center. All patients gave written consent.
Eligible patients were adults with moderately-to-severely active UC for at least 3 months with a Mayo score of 6Ϫ12 points (endoscopy subscore of at least 2), despite concurrent therapy with steroids and/or azathioprine or 6-mercaptopurine. The Mayo score is a composite score of 4 items (ie, rectal bleeding, stool frequency, physician's global assessment, endoscopy). 13 For the scoring of the rectal bleeding and stool frequency items, the worst score from the previous 3 days before the study visit was used. The diagnosis of UC was confirmed by biopsy obtained at the screening colonoscopy or flexible sigmoidoscopy. Patients concurrently treated with oral corticosteroids were to receive a stable dose (prednisone Ն20 mg/day for at least 2 weeks, or Ͻ20 mg/day for at least 40 days) before baseline. Patients treated with immunomodulators were to receive at least a consecutive 3-month course of azathioprine (at least 1.5 mg/kg/day, or highest tolerated dosage) or 6-mercaptopurine (at least 1 mg/ kg/day, or highest tolerated dosage) before baseline (with stable dosage for at least 4 weeks). Concurrent therapy was not required for patients who failed to respond to or could not tolerate previous corticosteroid or immunomodulator treatment, as judged by the investigator. Previous use of anti-TNF agents other than adalimumab was permitted if the patient had discontinued its use due to a loss of response or intolerance to the agent for longer than 8 weeks. Patients were allowed stable dosages of 5-aminosalicylates as concurrent therapy, but 5-aminosalicylate use was not an entry criterion for the trial.
Patients were excluded if they had the following: history of subtotal colectomy with ileorectostomy or colectomy with ileoanal pouch, Koch pouch, or ileostomy for UC, or planned bowel surgery; previous treatment with adalimumab; receipt of intravenous corticosteroids within 2 weeks of screening; receipt of cyclosporine, tacrolimus, or mycophenolate mofetil within 1 month of baseline; receipt of therapeutic enema or suppository, other than required for endoscopy, within 2 weeks of the screening endoscopy and during the screening period; or receipt of any investigational agent within 30 days or 5 half-lives before baseline. Patients were also excluded for the following: a current diagnosis of fulminant colitis or toxic megacolon, disease limited to the rectum (ulcerative proctitis), current diagnosis of indeterminate colitis, or current diagnosis or history of Crohn's disease, current total parenteral nutrition, positive Clostridium difficile stool assay, previous use of infliximab and no clinical response at any time ("primary nonresponder"), history of an infection requiring intravenous antimicrobial therapy within 1 month or oral antimicrobial therapy within 2 weeks, history of listeria, histoplasmosis, chronic or active hepatitis B infection, human immunodeficiency virus, immunodeficiency syndrome, or untreated tuberculosis, history of central nervous system demyelinating disease, history of malignancy other than a successfully treated nonmetastatic cutaneous squamous cell or basal cell carcinoma or localized carcinoma in situ of the cervix, or evidence of dysplasia or malignancy on the screening colonoscopy/flexible sigmoidoscopy with biopsy.
Study Design
Patients were randomly assigned in a 1:1 ratio to receive subcutaneous injections of adalimumab 160 mg at week 0, 80 mg at week 2 and then 40 mg EOW beginning at week 4, or matching placebo. They were followed through week 52. Randomization was performed centrally and was stratified by prior exposure to infliximab or other anti-TNF agents. Concomitant medication doses remained constant except steroids, which could be tapered after week 8 at the discretion of the investigator in patients who had a satisfactory clinical response. The taper consisted of reducing the prednisone dosage by 5 mg weekly until a dosage of 10 mg/day was reached. Thereafter, the dosage was reduced by 2.5 mg weekly until discontinuation. 
Efficacy Evaluations
Patients were evaluated at weeks 0, 2, 4, 8, 12, 16, 20, 26, 32, 38, 44, and 52/early termination. The Mayo score was determined at weeks 0, 8, 32, and 52/early termination. A partial Mayo Score (Mayo Score without endoscopy) was determined at all visits. Health-related quality of life, as measured by the Inflammatory Bowel Disease Questionnaire (IBDQ), 14 was determined at weeks 0, 4, 8, 20, 32, and 52/early termination. Clinical remission was defined as a total Mayo score Յ2 points, with no individual subscore exceeding 1 point. Clinical response was defined as a decrease from baseline in the total Mayo score by at least 3 points and at least 30% with an accompanying decrease in rectal bleeding subscore of at least 1 point or an absolute rectal bleeding subscore of 0 or 1. Mucosal healing was defined as an endoscopy subscore of 0 or 1. Clinical response, clinical remission, and mucosal healing were assessed at weeks 8, 32, and 52/early termination. Patients who achieved clinical remission or clinical response at both weeks 8 and 52 were considered to be in sustained clinical remission or sustained clinical response, respectively. Partial Mayo score clinical remission was defined as a partial Mayo score Յ2 points, with no individual subscore exceeding 1 point. IBDQ response was defined as an increase from baseline of at least 16 points.
Safety Evaluations
At each clinic visit from baseline (week 0) through week 52/early termination, patients underwent physical examination, vital signs, previous (at baseline) and concomitant medications, and adverse events were recorded, and general laboratory tests including C-reactive protein and urinalysis were performed. Sera were collected for determination of antibodies to adalimumab (weeks 0, 8, 32, and 52/early termination), adalimumab concentrations (weeks 0, 2, 4, 8, 32, and 52/early termination), antinuclear antibodies (weeks 0, 32, and 52/early termination), and double-stranded DNA antibodies (weeks 0, 32, and 52/early termination, performed only if antinuclear antibody was positive).
Statistical Methods
The primary efficacy analysis was performed on the intent-to-treat population and consisted of 2 co-primary efficacy end points: (1) proportion of patients achieving clinical remission at week 8 and (2) proportion of patients achieving clinical remission at week 52. Clinical remission per Mayo score was defined as Mayo score Յ2 with no subscore Ͼ1. Ranked secondary efficacy variables included: (1) the proportion of patients who achieved clinical remission at both weeks 8 and 52 (sustained); (2Ϫ4) clinical response (decrease in Mayo score of Ն3 points from baseline and decrease in Mayo score of Ն30% from baseline and decrease in the rectal bleeding score Ն1 or an absolute rectal bleeding score of 0 or 1) at week 8, week 52, and both weeks 8 and 52 (sustained); (5Ϫ7) mucosal healing (endoscopy subscore of 0 or 1) at week 8, week 52, and both weeks 8 and 52 (sustained); (8) proportion of patients who achieved remission at week 52 and discontinued corticosteroid use before week 52; or (12) for Ն90 days before week 52; (13) proportion of patients who discontinued corticosteroid use and achieved remission (sustained) at both weeks 32 and 52; (9) physician's global assessment subscore; (10) stool frequency subscore; and (11) proportion of patients with a rectal bleeding subscore indicative of mild disease (Յ1) at week 8; (15) proportion of patients who were IBDQ responders (defined as an increase Ն16 points) at week 8; and (14) at week 52. Additionally, ranked primary and secondary end points were analyzed after stratification by use of prior anti-TNF agent.
Demographic and baseline characteristics were summarized using descriptive statistics. Efficacy analyses were done in the intent-to-treat population. Exclusion of 3 sites from efficacy analyses occurred due to site noncompliance with good clinical practice and protocol requirements. Hypothesis testing for the ranked primary and secondary end points was carried out in a hierarchical order using a 2-sided Cochran-Mantel-Haenszel test adjusted for earlier exposure to infliximab or other anti-TNF agents at a significance level of .05. The confirmatory multiple testing procedure stopped at the first hypothesis that could not be rejected. This ensured that the multiple significance level was controlled at .05. Missing or incomplete data as well as values at or after switch to open-label treatment of adalimumab were handled using the nonresponder imputation methods. Comparison of treatment groups in subgroups of patients with or without prior anti-TNF treatment use were carried out using the 2 test or Fisher's exact test. Analyses of treatment-emergent adverse events were determined in the safety population, which included all patients who received at least 1 injection of study drug during the study. The numbers of patients experiencing adverse events were compared between the treatment groups using Fisher's exact test.
Sample Size
Assuming a remission rate of 5% in the placebo group at week 8 or week 52, a difference of at least 7 percentage points from the adalimumab group, and a 2-sided test at the .05 level, a sample size of 250 patients provided power of .80 to detect a difference between the treatment groups. Thus, a total of 500 patients were to be randomized in this study.
Results

Patients
Supplementary Figure 1 shows the disposition of patients. The baseline characteristics were similar in the 2 groups (Table 1) . Seventy-five percent (368 of 494) of patients in the overall population were currently receiving steroids and/or azathioprine/6-mercaptopurine. The remaining 25% of patients had previously failed and discontinued one or both of these agents, in the opinion of the investigator. Forty percent (199 of 494) of patients in the overall population had previously received and discontinued an anti-TNF agent.
Efficacy
Co-primary end points. At week 8, 16.5% of patients receiving adalimumab were in clinical remission as compared with 9.3% on placebo (P ϭ .019; absolute difference ϭ 7.2; 95% confidence interval: 1.2Ϫ12.9) ( Figure  1A ). At week 52, the corresponding values were 17.3% and 8.5%, respectively (P ϭ .004; absolute difference ϭ 8.8; 95% CI: 2.8Ϫ14.5) ( Figure 1A ). The efficacy of adalimumab was generally consistent among demographic and baseline disease characteristics ( Supplementary Figures  2A and B) .
Secondary endpoints and exploratory analyses.
Clinical response was achieved at week 8 in 50.4% of patients receiving adalimumab and 34.6% on placebo (P Ͻ .001) ( Figure 1B) . The corresponding values at week 52 were 30.2% and 18.3%, respectively (P ϭ .002) ( Figure 1B ). Mucosal healing was achieved at week 8 in 41.1% of patients receiving adalimumab and 31.7% of patients receiving placebo (P ϭ .032) ( Figure 1C ). The corresponding values at week 52 were 25% and 15.4%, respectively (P ϭ .009) ( Figure 1C ). For other secondary end points, differences also favored adalimumab over placebo, and all but one of the comparisons were significant at the P Ͻ .05 level ( Table 2) .
Prior Anti-TNF Use
Among patients who were naïve to anti-TNF agents, 21.3% of patients receiving adalimumab achieved clinical remission at week 8 as compared with 11% on placebo (P ϭ .017). The corresponding values at week 52 were 22% and 12.4% (P ϭ .029). At week 52, for antiTNF؊naïve patients, the number needed to treat (NNT) for clinical remission was 11 and the NNT for clinical response was 8. For other secondary end points, differences also favored adalimumab over placebo, and all but 3 of the comparisons were significant at the P Ͻ .05 level (Table 3) . Among the anti-TNF؊experienced patients, 9.2% of patients receiving adalimumab achieved clinical remission at week 8 as compared with 6.9% on placebo (P ϭ .559). The corresponding values at week 52 were 10.2% and 3%, respectively (P ϭ .039). For anti-TNF؊ex-
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perienced patients, week 52 NNT for clinical remission was 14 and week 52 NNT for clinical response was 10. For other secondary end points, differences generally favored adalimumab over placebo, but a majority of the comparisons were not significant (Table 3) .
Additional Analyses
Using the nonresponder imputation method, the proportion of patients achieving clinical remission based on the partial Mayo score was statistically significantly higher for adalimumab patients compared with placebo from week 2 on throughout the study (except for week 38; Figure 1D ) and the proportion of patients using corticosteroids at baseline who discontinued corticosteroid use ( Figure 1E ) tended to progressively increase over study visits. No patients underwent colectomy during the placebo-controlled trial. A subsequent publication will integrate the colectomy results from the current trial with the colectomy results from companion open-label extension studies.
Safety
Adalimumab treatment was generally well-tolerated and the overall safety profile of adalimumab was comparable with that of placebo. A similar proportion of patients in each study group experienced treatment emergent adverse events (Table 4) ; the incidence rate during double-blind treatment was numerically greater in the placebo group vs the adalimumab treatment group (846.1 events/100 patient-years vs 743.3 events/100 patient-years, respectively). The majority of patients experienced treatment emergent adverse events that were nonserious, mild, or moderate in severity, and were considered not related or probably not related to study drug by the investigator. A statistically significantly greater proportion of adalimumab-treated patients reported injection site-related and hematologic-related adverse events compared with placebo-treated patients. The latter adverse events (mostly leukopenia) were reported in adalimumab-treated patients who were all receiving concomitant immunosuppressants at baseline; all events were resolved by the end of the study.
There were no statistically significant differences between treatment groups for any of the other adverse events of special interest. However, the incidence of serious adverse events, severe adverse events, infectious adverse events, and adverse events leading to discontinuation tended to be higher in placebo-treated compared with adalimumabtreated patients (Table 4) . During double-blind treatment, 2 adalimumab-treated patients experienced malignancies (1 squamous cell carcinoma, 1 gastric cancer). There were no deaths or cases of demyelinating disease, lymphoma, or tuberculosis reported in this study. Analyses of laboratory parameters and vital signs did not reveal any additional safety issues. CRP, C-reactive protein; ITT, intent-to-treat; PGA, Physician's Global Assessment; 6-MP, 6-mercaptopurine; ULN, upper limit of normal. a 24 patients (14 placebo ϩ 10 adalimumab) were excluded due to site noncompliance. b n ϭ 246, placebo; n ϭ 247, adalimumab; n ϭ 493, total. c n ϭ 245, placebo; n ϭ 247, adalimumab; n ϭ 492, total. d n ϭ 247, adalimumab; n ϭ 493, total. e Includes mesalazine, sulphasalazine, balsalazide, aminosalicyclic acid, and olsalazine.
Antibodies to Adalimumab and Adalimumab Concentrations
Antibodies to adalimumab were detected in 2.9% (7 of 245) of patients in the adalimumab group with evaluable data on anti-adalimumab antibody status during double-blind treatment; all patients positive for antibodies to adalimumab received adalimumab monotherapy. The median serum trough concentrations for remitters vs nonremitters at weeks 8, 32, and 52/early termination are shown in Table 5 .
Discussion
Treatment with adalimumab demonstrated significant benefits over placebo in the rates of clinical remission at weeks 8 and 52 among patients with moderate-tosevere UC who had previously failed or were currently Restricted to patients using corticosteroids at baseline (placebo, n ϭ 140; adalimumab, n ϭ 150).
failing steroids and/or immunosuppressive therapy with azathioprine or 6-mercaptopurine (75% of patients were currently failing these medications). Substantial benefits were also seen for clinical response, mucosal healing, steroid discontinuation, IBDQ response, and other secondary end points. Incidence rates of treatment-emergent adverse events were similar across treatment groups, and no clinically important safety trends were identified. Our results confirm the findings of ULTRA 1, an 8-week induction trial with adalimumab in patients with UC, which demonstrated that adalimumab 160 mg at week 0, 80 mg at week 2, and then 40 mg EOW beginning at week 4 was effective for inducing clinical remission. 12 Of note, in the earlier study conducted by Reinisch and colleagues, 12 significant differences between the adalimumab and placebo groups were only achieved for 2 of the secondary end points at week 8, ie, rectal bleeding and Physician's Global Assessment subscores. In contrast, in ULTRA 2, significantly greater proportions of adalimumab-treated patients achieved almost all secondary end points at week 8. The discrepancy between the 2 trials might be due to the relatively high placebo response rates that were observed during ULTRA 1; whereas the placebo response rates observed in ULTRA 2 are generally similar to those reported in 2 large placebo-controlled trials of infliximab for UC. 2 When taken together, the results of ULTRA 1 and ULTRA 2 clearly demonstrate that adalimumab 160 mg at week 0, 80 mg at week 2, and then 40 mg EOW is an effective induction regimen for patients with UC. Because a plateau in the dose-response curve was not achieved in the dose-finding ULTRA 1 trial, it is unknown whether even higher induction doses of adalimumab might have greater efficacy.
The 52-week primary and secondary end points in ULTRA 2 provide evidence that adalimumab 40 mg EOW is effective for long-term/maintenance treatment of UC. Important long-term outcomes, including improved quality of life, steroid discontinuation, and achievement of steroid-free remission, also occurred more frequently during maintenance therapy with adalimumab. Additional information regarding other long-term outcomes such as reduction in the rates of hospitalization and colectomy, improved work productivity, etc, with adalimumab maintenance therapy is needed. These data will be reported in subsequent publications that will integrate the results of the current controlled trial with the results of companion open-label extension and induction studies to provide a greater likelihood of observing relatively rare events like e Among patients with baseline corticosteroid use: n ϭ 81 for placebo and n ϭ 110 for adalimumab (no prior anti-TNF); n ϭ 59 for placebo and n ϭ 40 for adalimumab (prior anti-TNF).
colectomy. Whether even higher maintenance doses of adalimumab, such as 40 mg weekly, might have greater efficacy is unknown. Of interest, a dose-finding maintenance trial with adalimumab in another form of inflammatory bowel disease, Crohn's disease, did not demonstrate a difference between 40 mg EOW and 40 mg weekly. 5 Forty percent of patients in ULTRA 2 had previously used anti-TNF therapy (excluding adalimumab) for the treatment of UC. Although earlier anti-TNF therapy was a stratification variable for randomization, the study was not powered to assess the efficacy of adalimumab in subgroups of patients who were naïve to anti-TNF therapy and who had received earlier anti-TNF therapy. Among the larger subgroup of patients who were naïve to anti-TNF therapy, both of the co-primary end points and a majority of the secondary end points were statistically significant, and the magnitude of effect was broadly comparable to the effects reported with infliximab in patients with UC who were naïve to anti-TNF therapy. Among the smaller subgroup of patients who had previously received anti-TNF therapy (predominantly with infliximab), there were numeric differences in favor of adalimumab, with statistically significantly higher week 52 remission and response rates in adalimumab-treated patients. The magnitude of effect was generally small for other end points, and for many of the comparisons was not significant. These observations should be interpreted with caution because it is a subgroup analysis, the total number of patients in this subgroup is small, and in other disease settings such as Crohn's disease the absolute treatment effect after prior anti-TNF therapy is smaller than the effect observed in anti-TNF naïve patients. 3, 4 The absolute differences in remission rates between adalimumab and placebo observed in our study are somewhat smaller than those observed in 2 trials of infliximab that had a somewhat similar design. 15 Direct comparison across different studies is complicated for several reasons. First, the infliximab trials were conducted 8؊10 years ago, when no approved medication option was available to patients with UC who had failed conventional therapy. Second, the infliximab trials did not allow patients with inadequate response or flare to leave the blinded trial and receive open-label rescue therapy. Thus, patients had to remain in the study or be discontinued. In the present trial, rescue therapy with open-label adalimumab was per- mitted. These patients were conservatively analyzed as failures, although they continued on adalimumab treatment in the trial. Bias could have been introduced if patients and or investigators judged the patients to have an inadequate response or flare in order for the patient to receive open-label therapy. Third, in the adalimumab trial, the Mayo score was calculated based on the worst score from the last 3 days for stool frequency and rectal bleeding. In contrast, in the infliximab trials and other UC trials, the average score for stool frequency and rectal bleeding from the last 3 days was used to calculate the Mayo score. Finally, the patients in the infliximab trials were anti-TNF؊naïve patients, whereas 40% of patients in the adalimumab trials had previously been exposed to anti-TNF agents. These differences in clinical trial design and patient populations limit across-trial comparisons. How should the results of this trial be incorporated into clinical practice? We studied outpatients with moderate-to-severe UC failing therapy with steroids and/or immunosuppressives. Subgroup analysis showed the strongest effect in patients who were naïve to anti-TNF therapy. Thus, the results of ULTRA 2 suggest that the ideal patient population for adalimumab is outpatients with moderate-to-severe UC, failing steroids and/or immunosuppressives, who are anti-TNF therapy-naïve, and who desire the convenience of subcutaneous dosing. However, statistically significant benefit for anti-TNF-experienced patients receiving adalimumab over placebo in terms of clinical remission and response at week 52, as well as sustained clinical response, might offer an additional treatment option to patients who have already failed or did not tolerate infliximab. Adalimumab has not been studied in hospitalized patients with severe UC who are failing intravenous steroids.
The overall safety profile of adalimumab observed in this study was similar to that seen in other trials of adalimumab in patients with inflammatory bowel disease. 12, 16 Notably, higher incidence rates were observed for adverse events, severe adverse events, serious adverse events, serious infectious adverse events, and serious infectious adverse events in patients receiving placebo as compared with those receiving adalimumab. A significantly greater proportion of adalimumab-treated patients experienced injection-site reactions. Almost all events were mild and none required discontinuation of study drug therapy. In addition, 2 malignancies were reported in adalimumab-treated patients, 1 squamous cell carcinoma and 1 gastric cancer in a patient with known risk factors.
Similar to reports with other anti-TNF antibodies administered systematically without dose interruption, 1, 17 the rate of formation of antibodies to adalimumab (antidrug antibodies) during 1 year was lower in patients receiving combination therapy with adalimumab and an immunosuppressive agent as compared with patients receiving monotherapy with adalimumab. The median trough serum adalimumab concentrations were higher in patients who achieved remission at week 8 and week 52 as compared with patients who did not achieve remission.
These findings raise the possibilities that adalimumab therapy for UC could be further optimized by the concomitant administration of azathioprine and by the use of therapeutic drug monitoring to customize adalimumab dosing to achieve the higher median trough concentrations observed among patients who responded to adalimumab therapy. However, as this study was not designed to prospectively treat to a target serum drug concentration, these results should be interpreted with caution.
In conclusion, adalimumab was more effective than placebo for inducing and maintaining clinical remission in patients with moderate-to-severe UC who did not adequately respond to conventional therapy with oral corticosteroids or immunosuppressive agents.
